A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Protocol: 
AAAK7800
Phase: 
I/II

A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer

Are you Eligible? (Inclusion Criteria)

1. 18 to 85 years of age at time of study enrollment.
2. Able to meet the requirements of the study, give voluntary, written
informed consent, and must be able to adhere to dosing and visit schedules.
3. Has a diagnosis of low-grade (G1 or G2), uni- or multifocal papillary-
appearing bladder tumor, stage Ta.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States